(NASDAQ: CRVO) Cervomed's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.22%.
Cervomed's earnings in 2026 is -$30,349,743.On average, 8 Wall Street analysts forecast CRVO's earnings for 2026 to be -$41,175,346, with the lowest CRVO earnings forecast at -$64,304,539, and the highest CRVO earnings forecast at -$22,225,071. On average, 7 Wall Street analysts forecast CRVO's earnings for 2027 to be -$35,222,958, with the lowest CRVO earnings forecast at -$68,156,885, and the highest CRVO earnings forecast at -$15,875,051.
In 2028, CRVO is forecast to generate -$16,963,626 in earnings, with the lowest earnings forecast at -$23,114,074 and the highest earnings forecast at -$13,176,292.